Available Until 7/15/2025
View Cart

Emergency Medicine Specialty Recertification Literature Study: Module 1A-B (Cert #L249135)

ACPE Numbers: Various – see listing below
Content Release Date: 07/17/2024
Expiration Dates: 07/15/2025
Activity Type: Application-based
CE Credits: 10 hours (BPS and ACPE)
Activity Fee: $60 (ASHP member); $115 (non-member)

Activity Overview

The Literature Study Module is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). This module consists of 2online home study activities (see table below). Each activity is designed to assess the learners’ ability to analyze and apply peer-selected contemporary articles to practice. 

Module 1A – Cardiology/Trauma: This module focuses on current issues in the management of cardiovascular and trauma related emergencies. Topics include arrhythmias, acute pulmonary edema, and acute traumatic hemorrhage. 

Module 1B – Neurology/Critical Care: This module focuses on current issues in the management of neurologic emergencies and critically ill patients. Topics include acute cerebral hemorrhage, ischemic stroke, rapid sequence intubation, and life-threatening toxicity due to poisonings. 

Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this Literature Study, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice. 

These activities are part of the ASHP and ACCP professional development program for BCEMP recertification approved by the BPS. 

Accreditation

ACPE Provider with Commendation logoThe American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

  

    

The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

These Literature Studies are designed to help board-certified pharmacists who are seeking recertification credit hours to maintain their Board of Pharmacy Specialties (BPS).

Board certified pharmacists are eligible to receive up to 10 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline.   

ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost.

ASHP and ACCP are approved by BPS as providers for the recertification of BCEMP.

Learning Activity

ACPE Number

Contact Hours (ACPE and BPS)

Assessment Pass Point

Module 1A: Cardiology/Trauma

0204-9999-24-944-H01-P

5.0

 76%

Module 1B: Neurology/Critical Care

0204-9999-24-945-H01-P

5.0

 80%

Module 1A: Cardiology/Trauma
ACPE #: 0204-9999-24-944-H01-P

This module focuses on current issues in the management of cardiovascular and trauma related emergencies. Topics include arrhythmias, acute pulmonary edema, and acute traumatic hemorrhage. 

Rahimi M, Dorian P, Cheskes S, et al. Effect of time to treatment with antiarrhythmic drugs on survival and neurological outcomes in shock refractory out-of-hospital cardiac arrest. Crit Care Med 2023; 51: 903-912.

  • Describe the post-hoc analysis by Rahimi and colleagues of the Resuscitation Outcomes Consortium Amiodarone, Lidocaine, and Placebo Study (ROC ALPS) comparing amiodarone with lidocaine for the treatment of ventricular fibrillation or pulseless ventricular tachycardia in patients with shock-refractory out‐of‐hospital cardiac arrest (OHCA)
  • Develop recommendations for the use of amiodarone and lidocaine in patients with out-of-hospital cardiac arrest (OHCA) and shock-refractory ventricular fibrillation or pulseless ventricular tachycardia 

Ray L, Geier C, DeWitt KM. Pathophysiology and treatment of adults with arrhythmias in the emergency department, part 2: ventricular and bradyarrhythmias. Am J Health-Syst Pharm 2023; 80: 1123-1136.

  • Describe the pathophysiology and treatment of ventricular arrhythmias and bradyarrhythmias in adults
  • Develop recommendations for the treatment of ventricular arrhythmias and bradyarrhythmias in adults in the emergency department

Houseman BS, Martinelli AN, Oliver WD, Devabhakthuni, Mattu A. High-dose nitroglycerin infusion description of safety and efficacy in sympathetic crashing acute pulmonary edema: the HI-DOSE SCAPE study. Am J Emerg Med 2023; 63: 74-78.

  • Describe the HI-DOSE SCAPE study by Houseman and colleagues of high-dose nitroglycerin (HDN) infusion for sympathetic crashing acute pulmonary edema (SCAPE)
  • Develop recommendations for the use of high-dose nitroglycerin (HDN) infusion and adjunct therapies in patients with sympathetic crashing acute pulmonary edema (SCAPE) 

Bouzat P, Charbit J, Abback PS, et al; PROCOAG Study Group. Efficacy and Safety of Early Administration of 4-Factor Prothrombin Complex Concentrate in Patients With Trauma at Risk of Massive Transfusion: The PROCOAG Randomized Clinical Trial. JAMA. 2023; 329(16):1367-1375.

  • Describe the PROCOAG study of four-factor prothrombin complex concentrate (4F-PCC) in patients with trauma at risk of massive transfusion
  • Develop recommendations for the use of four-factor prothrombin complex concentrate (4F-PCC) to treat patients with trauma at risk of massive transfusion 

The PATCH-Trauma Investigators and the ANZICS Clinical Trials Group. Prehospital tranexamic acid for severe trauma. N Engl J Med 2023; 389:127-136.

  • ​Describe the Pre-hospital Antifibrinolytics for Traumatic Coagulopathy and Hemorrhage (PATCH-Trauma) trial of tranexamic acid in adults with major trauma and suspected trauma-induced coagulopathy​
  • ​Develop recommendations for the prehospital administration of tranexamic acid to adults with major trauma and suspected trauma-induced coagulopathy who are being treated in advanced trauma systems​ 

Sigmon J, Crowley KL, Groth CM. Therapeutic review: the role of tranexamic acid in management of traumatic brain injury, nontraumatic intracranial hemorrhage, and aneurysmal subarachnoid hemorrhage. Am J Health Syst Pharm. 2023;80:1213-1222.

  • Describe the use of tranexamic acid in patients with intracranial hemorrhage (ICH) associated with traumatic brain injury (TBI), nontraumatic (i.e., spontaneous) ICH, and aneurysmal subarachnoid hemorrhage (aSAH)
  • Develop recommendations for the use of tranexamic acid in patients with intracranial hemorrhage (ICH) associated with traumatic brain injury (TBI), nontraumatic (i.e., spontaneous) ICH, and aneurysmal subarachnoid hemorrhage (aSAH) 

Gregory H, Aljadeed R, Desai D, et al. Recommendations for nonantidote medications needed in the emergency department during a mass casualty incident. Am J Health Syst Pharm. 2023;80:779-785.

  • Describe management plans and medications used in the emergency department during a mass casualty incident
  • Develop management plans and recommendations for the use of medications in the emergency department during a mass casualty incident

Module 1B: Neurology/Critical Care
ACPE #: 0204-9999-24-945-H01-P

This module focuses on current issues in the management of neurologic emergencies and critically ill patients. Topics include acute cerebral hemorrhage, ischemic stroke, rapid sequence intubation, and life-threatening toxicity due to poisonings. 

Ma L, Hu X, Song L, et al. The third intensive care bundle with blood pressure reduction in acute cerebral haemorrhage trial (INTERACT3): an international, stepped wedge cluster randomized controlled trial. Lancet 2023; 402: 27-40.

  • Describe the third Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3)
  • Develop recommendations for the treatment of patients with acute spontaneous intracerebral hemorrhage 

Hoh BL, Ko NU, Amin-Hanjani S, et al. 2023 Guideline for the Management of Patients With Aneurysmal Subarachnoid Hemorrhage: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2023 Jul;54(7):e314-e370. 

Focus on ED care: 1-Introduction (e316-319), 2-Gen'l Concepts (e319-322), 6-Medical Measures to Prevent Rebleeding after aSAH (e326-327), 8.5 - Management of Seizures Associated with aSAH (e344-346).

  • Describe the 2023 guideline from the American Heart Association (AHA)/American Stroke Association (ASA) for the management of patients with aneurysmal subarachnoid hemorrhage (aSAH)
  • Develop recommendations for the use of drug therapies in patients with aneurysmal subarachnoid hemorrhage (aSAH) 

Chen H, Cui Y, Zhou Z, et al. Dual antiplatelet therapy vs alteplase for patients with minor nondisabling acute ischemic stroke: The ARAMIS randomized clinical trial. JAMA 2023; 329: 2135-2144.

  • Describe the Antiplatelet vs R-tPA for Acute Mild Ischemic Stroke (ARAMIS) study by Chen and colleagues
  • Develop recommendations for the treatment of patients with minor nondisabling acute ischemic stroke 

Acquisto NM, Mosier JM, Bittner EA, et al. Society of Critical Care Medicine clinical practice guidelines for rapid sequence intubation in the critically ill patient. Crit Care Med. 2023;51:1411-1430.

  • Describe the Society of Critical Care Medicine (SCCM) clinical practice guidelines for rapid sequence intubation in the critically ill patient
  • Develop recommendations for rapid sequence intubation in critically ill patients 

Lavonas EJ, Akpunonu PD, Arens AM, et al. 2023 American Heart Association focused update on the management of patients with cardiac arrest or life-threatening toxicity due to poisoning: an update to the American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 2023; e149 - e184.

  • Describe the 2023 American Heart Association (AHA) focused update on the management of patients with cardiac arrest or life-threatening toxicity due to poisoning
  • Develop recommendations for the management of patients with cardiac arrest or life-threatening toxicity due to poisoning

Full Faculty Bios

Heather Draper, PharmD, BCPS, BCEMP*
Clinical Pharmacy Specialist, Emergency Medicine
Mercy Health Saint Mary's
Grand Rapids, Michigan

Curtis Geier, PharmD, BCCCP
Emergency Medicine Clinical Pharmacist
Zuckerberg San Francisco General Hospital/San Francisco Department of Public Health
San Francisco, CA 

Jennifer Hoh, PharmD, BCCCP, BCEMP
Clinical Assistant Professor of Pharmacy Practice - Emergency Medicine
University of Louisiana at Monroe College of Pharmacy
Director, PGY1 Pharmacy Practice Residency
New Orleans, Louisiana  

Ashley Martinelli, PharmD, BCCCP, BCEMP
Clinical Pharmacy Specialist, Emergency Medicine
University of Maryland Medical Center
Baltimore, Maryland 

Megan Musselman, PharmD, MS, BCPS, BCCCP, BCEMP*
PGY2 Emergency Medicine Residency Program Director
North Kansas City Hospital
Kansas City, Missouri 

Gabrielle Procopio, PharmD, BCPS
Emergency Medicine Clinical Pharmacist
Hackensack University Medical Center
Assistant Professor of Emergency Medicine
Hackensack Meridian School of Medicine
Hackensack, New Jersey 

David Zimmerman, PharmD, BCCCP, BCEMP*
Associate Professor of Pharmacy
Duquesne University
Emergency Medicine Pharmacist
University of Pittsburgh Medical Center-Mercy
Pittsburgh, Pennsylvania

* Content Matter Experts

Anna Jackson, PharmD, BCPS

Zachary Benzio, PharmD, BCEMP
Eric Berg, PharmD, BCEMP
Michelle Blesso, PharmD, BCPS, BCEMP
Jessica Boben, PharmD, BCPS, BCEMP
Justin Booth, PharmD, BCEMP
Taylor Cason, PharmD, CPP, BCPS, BCEMP
Allison Clarke, PharmD, BCPS, BCEMP
Jaclyn Connors, PharmD, BCEMP
Phillip Cook, PharmD, BCPS, BCCCP, BCEMP
Katelyn Corcoran, PharmD, BCEMP
Jessica Corio, PharmD, BCPS, BCEMP
Sarah Elizabeth Davis, PharmD, BCEMP
Sarah DiVello, PharmD, BCPS, BCEMP
Kellyn Engstrom, PharmD, MPH, BCEMP
Lanting Fuh, PharmD, BCEMP, BCPS
Haden Geiger, PharmD, BCEMP
Bryan Gendron, PharmD, BCPS, BCEMP
Jillien Hankewich, BScPharm, BCEMP
Danielle Hopwood, PharmD, BCPS, BCEMP
Tara Jawaro, PharmD BCPS, BCEMP
Weina Jiang, PharmD, BCPS, BCEMP
Vivian Kum, PharmD, BCEMP
Jason Lew, PharmD, BCPS, BCEMP
Ashley Lock, PharmD, BCPS, BCEMP
Samantha Luciana, PharmD, BCPS, BCEMP
Laura MacCall, BCPS, BCEMP
Jessica Mason, PharmD, BCEMP
Christina Metrejean, PharmD, BCEMP
Matthew Morrison, PharmD, BCPS, BCEMP
Mahmoud Nasiri, PharmD, BCPS, BCEMP
Ana Negrete, PharmD, BCPS, BCEMP
Belinda Nguyen, PharmD, BCPS, BCEMP
Kristen O'Brien, PharmD, BCEMP, DABAT
Mary O'Keefe, PharmD, BCEMP
Wesley Oliver, PharmD, MS, BCEMP
Tara Parish, PharmD, BCPS, BCCCP, BCEMP
Ben Peacock, PharmD, BCEMP
Cody Pitts, PharmD, BCPS, BCEMP
Mia Rafferty, PharmD, BCEMP
Alyssa Robertson, PharmD, BCPS, BCCCP, BCEMP
Christian Ruiz, PharmD, BCEMP
Kaitlin Rzasa, PharmD, BCPS, BCEMP
Kyle Schuchter, PharmD, BCEMP
Joe Spillane, PharmD, BCEMP, DABAT
Brett Stoecklein, PharmD, BCEMP
Louisa Sullivan, PharmD, BCPS, BCEMP
Brittany Turner, PharmD, BCPS, BCEMP
Amanda Vanderwerf, PharmD, BCEMP
John Vardsveen, PharmD, BCNP, BCEMP
Zakarri Vinson, PharmD, BCPS, BCEMP
Samantha Wagner, PharmD, BCEMP
Kerry Ward, PharmD, BCPS, BCCCP, BCEMP
Caroline Welch, PharmD, BCEMP
Stephanie Wong, PharmD, BCEMP
Sebin Yang, PharmD, BCEMP
Elmira Zamanpour, PharmD, BCCCP, BCEMP
Abigail Zeiner, PharmD, BCPS, BCEMP 

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company. 

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience. 

The following persons in control of this activity’s content have relevant financial relationships:

David Zimmerman: Investigator; ADMA Biologics 

All other persons in control of content do not have any relevant financial relationships with an ineligible company. 

As required by the Standards of Integrity and Independence in Accredited Continuing Education, all relevant financial relationships have been mitigated prior to the CPE activity.

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

  • Complete the attestation statement
  • Review all content
  • Complete and pass the assessments
  • Complete the evaluations 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

ASHP and ACCP collaborate on emergency medicine activities.

.